Heart Rhythm

Hearts should have normal rhythm to their beats, but when these beats are out of synch, it causes inefficient pumping of blood. Irregular heart arrhythmias occur when the electrical signals that coordinate the heart's beats do not work properly. This can cause beats that are too fast (tachycardia), or too slow (bradycardia). Tachycardias include atrial fibrillation (AFib), supraventricular tachycardia, ventricular fibrillation, and ventricular tachycardia (VT). Bradycardias include sick sinus syndrome and conduction block. Electrophysiology arrhythmia treatments include medications, life style changes, and the EP lab interventions of catheter ablation, and implantable pacemakers or defibrillators.

RSS icon
Vivek Reddy, MD, Director, Cardiac Arrhythmia Service, and the Leona M. and Harry B. Helmsley Charitable Trust Professor of Medicine in Cardiac Electrophysiology, at Mount Sinai in New York, was involved in most of the late-breaking pulsed field ablation (PFA) trials at the Heart Rhythm Society (HRS) 2024 meeting. He offers an overview of the new data presented and his observations from using PFA. #HRS24 #HRS2024 #PFA #EPeeps

The future of electrophysiology: Reviewing key trends in PFA

Vivek Reddy, MD, was involved in most of the late-breaking pulsed field ablation trials at Heart Rhythm 2024. He spoke to Cardiovascular Business at the conference about those trials and what they mean going forward.

Elutia, a Maryland-based healthcare technology company, has received clearance from the U.S. Food and Drug Administration (FDA) for EluPro, its new biologic envelope specifically designed for patients with implantable pacemakers and defibrillators. It was also cleared for use when implanting other types of devices, including neurostimulators and neuromodulators.

FDA clears new drug-eluting envelope for implantable cardiac devices—CEO sees it as ‘tip of the iceberg’

Elutia, formerly known as Aziyo Biologics, is already targeting additional uses for the newly approved device. 

Video interview with Matthew Reynolds, MD, who shares data on largest wearable ambulatory cardiac monitoring studies to date from the EXCALIBER and CAMELOT trials at HRS 2024. #HRS #HRS2024 #Remotemonitoring

First large-scale studies of wearable ambulatory cardiac monitoring shed light on usage 

Matthew Reynolds, MD, Lahey Hospital and Medical Center, explains data from the EXCALIBER and CAMELOT studies that show ambulatory cardiac monitoring usage among more than 300,000 patients.

healthcare value value-based care money dollar

Medical device company raises $104M to fund PFA research

Early research suggests Kardium's PFA system could give cardiologists a new tool for the fight against atrial fibrillation. The company plans to study its technology even more with this latest round of funding. 

Diamond Shruumz microdosing chocolate bars cookie butter flavor

FDA warns against ‘microdosing’ with mushroom chocolates due to heart issues, other health risks

According to the FDA, a total of 10 people have been hospitalized due to symptoms associated with these products. They are marketed as a "leading form of microdosing."

Stuart Connolly, MD, a veteran cardiologist known for his groundbreaking work in the field of electrophysiology, died June 2 after a long battle with neuroendocrine cancer.

Cardiologist Stuart Connolly remembered as a ‘generational thinker,’ electrophysiology pioneer

Connolly spent 40 years at McMaster University as a professor and researcher, founding the school’s cardiac arrhythmia service line and serving as its cardiology chair. He remained active in electrophysiology research until the end of his life.

Paul Zei, MD, director of the comprehensive atrial fibrillation program at Brigham and Women’s Hospital, explained key findings from the late-breaking REAL-AF Registry at the Heart Rhythm Society (HRS) 2024 conference. This registry study evaluated the short- and long-term outcomes of radiofrequency ablation (RF) in treating both paroxysmal atrial fibrillation (PAF) and persistent atrial fibrillation (PsAF), revealing significant advancements in procedural techniques and patient safety. #EPeeps #HRS2024

Interest growing in fluoroscopy-free workflows during RF ablation

Paul Zei, MD, discusses late-breaking data from the REAL-AF Registry, which looked at the short- and long-term outcomes of radiofrequency ablation in paroxysmal and persistent atrial fibrillation.

Jagmeet Singh, MD, PhD, Professor of Medicine, Harvard Medical School, and Founding Director of the Resynchronization and Advanced Cardiac Therapeutics Program at Mass General Hospital, delivered a key note address at HRS 2024 on the future of artificial intelligence in EP and AI applications in cardiology. #HRS #EPeeps #HRS2024 #HRS24 #HealthAI

Embracing AI to enhance EP: Insights from cardiologist Jagmeet Singh

Jagmeet Singh, MD, delivered a keynote address at HRS 2024 on the future of AI in electrophysiology. He spoke to Cardiovascular Business, sharing additional thoughts about the topic.

Displaying 33 - 40 of 1032

Around the web

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

 

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.

Design by Adaptive Theme
Trimed Popup
Trimed Popup